Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force
- PMID: 15897536
Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force
Abstract
This statement summarizes the U.S. Preventive Services Task Force recommendations on hormone therapy for the prevention of chronic conditions in postmenopausal women and the supporting scientific evidence, and updates the Task Force's 2002 recommendations on hormone replacement therapy. The updated statement is based on the results of the Women's Health Initiative randomized, controlled trial, as well as the information in the 2002 summary of the evidence on this topic, which is available on the USPSTF Web site (http://www.preventiveservices.ahrq.gov).
Summary for patients in
-
Summaries for patients. Hormone therapy to prevent chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force.Ann Intern Med. 2005 May 17;142(10):I59. doi: 10.7326/0003-4819-142-10-200505170-00004. Ann Intern Med. 2005. PMID: 15897529 No abstract available.
Similar articles
-
Summaries for patients. Postmenopausal hormone replacement therapy to prevent chronic conditions: recommendations from the U.S. Preventive Services Task Force.Ann Intern Med. 2002 Nov 19;137(10):I48. Ann Intern Med. 2002. PMID: 12435233 No abstract available.
-
Summaries for patients. Hormone therapy to prevent chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force.Ann Intern Med. 2005 May 17;142(10):I59. doi: 10.7326/0003-4819-142-10-200505170-00004. Ann Intern Med. 2005. PMID: 15897529 No abstract available.
-
Postmenopausal hormone replacement therapy for the primary prevention of chronic condition. Recommendations and rationale. U.S. Preventive Services Task Force.Am Fam Physician. 2003 Jan 15;67(2):358-64. Am Fam Physician. 2003. PMID: 12562158 No abstract available.
-
Postmenopausal hormone therapy before and after the women's health initiative study: what consequences?Ann Med. 2004;36(6):402-13. doi: 10.1080/07853890410035430. Ann Med. 2004. PMID: 15513292 Review.
-
Clinical appraisal of the Women's Health Initiative.J Obstet Gynaecol Res. 2005 Apr;31(2):80-93. doi: 10.1111/j.1447-0756.2005.00251.x. J Obstet Gynaecol Res. 2005. PMID: 15771632 Review. No abstract available.
Cited by
-
Efficacy and safety of lemborexant in midlife women with insomnia disorder.Menopause. 2023 Aug 1;30(8):839-848. doi: 10.1097/GME.0000000000002209. Epub 2023 Jun 20. Menopause. 2023. PMID: 37339396 Free PMC article. Clinical Trial.
-
Posttraumatic Stress Disorder and Likelihood of Hormone Therapy Use among Women in the Nurses' Health Study II: A 26-Year Prospective Analysis.Cancer Epidemiol Biomarkers Prev. 2021 Mar;30(3):492-498. doi: 10.1158/1055-9965.EPI-20-1227. Epub 2020 Dec 21. Cancer Epidemiol Biomarkers Prev. 2021. PMID: 33355196 Free PMC article.
-
Hormone Replacement Therapy: Lebanese Women's Awareness, Perception, and Acceptance.Obstet Gynecol Int. 2020 Jun 16;2020:5240932. doi: 10.1155/2020/5240932. eCollection 2020. Obstet Gynecol Int. 2020. PMID: 32607105 Free PMC article.
-
Treating chronic insomnia in postmenopausal women: a randomized clinical trial comparing cognitive-behavioral therapy for insomnia, sleep restriction therapy, and sleep hygiene education.Sleep. 2019 Feb 1;42(2):zsy217. doi: 10.1093/sleep/zsy217. Sleep. 2019. PMID: 30481333 Free PMC article. Clinical Trial.
-
Active agents, biomaterials, and technologies to improve biolubrication and strengthen soft tissues.Biomaterials. 2018 Oct;181:210-226. doi: 10.1016/j.biomaterials.2018.07.040. Epub 2018 Jul 26. Biomaterials. 2018. PMID: 30092370 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical